Developer docs
API playgroundTry for free, no card

Search company profiles

Explicyte

Full company profile

uuid000q2om

Namestring
Explicyte
Legal namestring
Immusmol SAS
Websiteurl
explicyte.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Explicyte is a specialty contract research organization (CRO) focused on precision oncology and immuno-oncology, founded in 2015 by Dr. Alban Bessède and headquartered at the Institut Bergonié Comprehensive Cancer Center in Bordeaux, France. The company delivers research services spanning target discovery, preclinical development, and clinical biomarker analysis for solid tumor drug development, with a particular emphasis on tumor microenvironment and immunotherapy-response biomarkers. Its core technical stack is anchored on a multi-omics spatial biology platform that combines 10x Genomics Xenium single-cell spatial transcriptomics, 10x Visium HD whole-transcriptome spatial profiling, Nanostring GeoMx DSP digital spatial profiling, 10x Chromium X single-cell RNA sequencing, Olink proteomics, flow cytometry, and AI-assisted multiplex IHC/IF digital pathology. Explicyte differentiates through proprietary assays including an ISO-certified multiplex IF assay for tertiary lymphoid structure (TLS) detection and a combined immune contexture panel that integrates CD8 spatial distribution, TLS maturity, and M2 macrophage scoring to predict immunotherapy response in NSCLC. The company is a 10x Genomics Certified Service Provider (the first such provider in France for Xenium studies) and holds ISO 13485:2016 and ISO 9001:2015 certifications for clinical tissue biomarker services.

Explicyte generates revenue through project-based contract research engagements sold to biotechnology companies, pharmaceutical companies, AI/computational biology firms, and comprehensive cancer centers across Europe, North America, and Asia. Pricing is quote-based and negotiated per study with deposit requirements and 30-day payment terms; no standardized tiers are published. The go-to-market model combines direct enterprise sales through PhD-level study directors, presence at major oncology conferences (AACR, ASCO, SITC, ESMO), peer-reviewed publications (40+ in 5 years in Nature, Cell, and cancer-focused journals), co-branded webinars, and free-access therapeutic-program databases used for lead generation. Named enterprise and academic customers include Bayer, GSK, AstraZeneca, Domain Therapeutics, Bioptimus, Cure51, Institut Bergonié, and Gustave Roussy. Beyond service revenue, the company is beginning to monetize proprietary target landscaping through publicly available therapeutic-program databases on anti-STEAP1/2 and anti-Claudin programs.

The operating entity is a brand under Immusmol SAS (Bordeaux-registered private limited company with €50,000 share capital). Explicyte is founder-led with no disclosed external institutional investors or funding rounds. The operating team comprises 25 scientists spanning cell biology, digital pathology, medical oncology, and data science (5 on-site data scientists), supported by a leadership team of CEO (Alban Bessède), CTO (Jean-Philippe Guégan, PhD), CSO (Imane Nafia, PhD), and COO (Loïc Cerf, MSc). The company has processed 10,000+ samples and validated 150+ tumor and immune markers across sponsored studies; two 10x Xenium instruments are now in operation, doubling single-cell spatial transcriptomics capacity compared with 2024.

Short descriptiontext

Explicyte is a France-based specialty contract research organization serving biotech, pharmaceutical, AI-bio, and academic cancer-center clients with spatial biology, single-cell, proteomics, and AI-assisted digital pathology services for precision oncology and immuno-oncology drug development.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBordeaux, France
HQ citystring
Bordeaux
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
preclinical CRO services, spatial transcriptomics services, immuno-oncology research, biomarker discovery services, digital pathology services
Industry6 codes
PRIMARYHLAGANAC
Single-Cell & Spatial Omics Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAGANAI
Bioinformatics, Multi-Omics Data Analysis & Interpretation Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAGADAG
Proteomics & Biomarker Analytical Testing
SECONDARYHLAAAIAF
Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code4 codes
  • Medical and Diagnostic Laboratories62151
  • Medical Laboratories621511
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code3 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Medical Laboratories8071
  • Services-Misc Health & Allied Services, Nec8090
Product category
Preclinical Contract Research Services
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Research Services
TypeProfessional Services
Description

Project-based contract research services for precision oncology and immuno-oncology drug development. Services span discovery (target identification), preclinical (cell-based assays, in vivo models), and clinical (biomarker analysis) stages. Pricing is quote-based, negotiated per study with deposit requirements and 30-day payment terms.

explicyte.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Pricing details1 tier
1Other
ModelOtherBilling cadencePay-as-you-go
Notes

Custom project-based pricing. No standard tiers or public pricing. Each service proposal is tailored to client requirements with deposits and milestone-based invoicing.

explicyte.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Explicyte is a specialty contract research organization offering integrated research services in precision oncology and immuno-oncology, from target discovery through preclinical and clinical biomarker analysis. Core capabilities include spatial transcriptomics on the full 10x Genomics suite (Xenium, Visium HD, Chromium X), Nanostring GeoMx DSP digital spatial profiling, automated multiplex IHC/IF digital pathology, single-cell RNA sequencing, cell-based immuno-oncology assays, Olink proteomics, flow cytometry, and bioinformatics, delivered under ISO 13485 and ISO 9001 certifications. Services are sold as project-based studies with custom proposals, deposits, and milestone-based invoicing to biotech, pharma, AI, and academic clients worldwide.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 30+ peer-reviewed publications in the past 5 years demonstrating scientific expertise in immuno-oncology
+2 more records
Product overview1 text field

Explicyte is a specialty contract research organization (CRO) offering integrated research services in precision oncology and immuno-oncology. The company operates a modular service portfolio spanning target discovery, preclinical development, and clinical biomarker support. Core capabilities include spatial transcriptomics (Xenium, Visium HD, GeoMx), digital pathology (multiplex IHC/IF), cell-based assays, single-cell RNA sequencing (10x Chromium), Olink proteomics, flow cytometry, and bioinformatics. Services are delivered from discovery through clinical trial phases, with ISO 13485/9001 certification for clinical-stage biomarker assays. The company is a 10x Genomics Certified Service Provider across its full spatial and single-cell biology portfolio. Key platforms include spatial transcriptomics for spatial biomarker analysis, cell-based assays for preclinical efficacy and mechanism-of-action studies, digital pathology with AI-driven image analysis, and integrated multi-omics combining transcriptomics, proteomics, and digital pathology.

Product and service11 records
1Spatial Transcriptomics Services
CategorySpatial Biology / Spatial Transcriptomics
Description

Spatially resolved transcriptomic profiling using the Nanostring GeoMx Digital Spatial Profiler (WTA, ~18k genes), the 10x Xenium single-cell spatial transcriptomics platform (up to 5K genes), and 10x Visium HD whole-transcriptome spatial biology. Includes custom tissue processing, QC, and bioinformatics analysis on FFPE tumor samples for biotech, pharma, and academic sponsors.

2Digital Pathology Services
CategoryDigital Pathology
Description

Automated multiplex immunofluorescence (mIF) and immunohistochemistry (IHC) staining with high-throughput whole-slide imaging and AI- and/or pathologist-assisted standardized scoring workflows. Validated 150+ tumor and immune markers across sponsored studies for immuno-oncology sponsors.

3Cell-Based Assays for Immuno-Oncology
4Biomarker Discovery & Testing Services
5Single-Cell RNA Sequencing Services
6Olink Proteomics Services
7Flow Cytometry Services
8Target Discovery Services
9In Vivo Syngeneic Tumor Models
10TLS Detection & Scoring Service
CategoryClinical Biomarker Services
Description

ISO-certified multiplex immunofluorescence (IF) panel for standardized detection and scoring of tertiary lymphoid structures (TLS) in tumor samples. Identifies patients most likely to benefit from cancer immunotherapies. Developed over 5+ years of translational research with publications in Nature Cancer and Nature Medicine.

11Bioinformatics & Data Science Services
CategoryBioinformatics / Data Science
Description

Custom data analysis for spatial transcriptomics, bulk RNA-seq, GeoMx DSP datasets, and digitized pathology slides. 10x Genomics data analysis services with 4-week turnaround delivered by 5 on-site data scientists combining computational pipelines with biological interpretation.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-01-01
Description

Certified Service Provider partnership for the full 10x Genomics single-cell and spatial biology portfolio including Chromium X, Visium HD, and Xenium platforms. Enables Explicyte to provide validated spatial transcriptomics services on FFPE tumor samples using industry-leading technology platforms.

2Institut Bergonié
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Comprehensive partnership for translational research programs in immuno-oncology. Located at the Institut Bergonié Comprehensive Cancer Center, Explicyte collaborates on clinical trials, biomarker discovery studies, and shares access to clinical samples and expertise. Multiple joint publications in Nature Cancer, Nature Medicine, and other journals.

explicyte.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration on multiple clinical trials and translational research programs including PEMBROSARC, REGOMUNE, and precision medicine studies. Joint publications on tertiary lymphoid structures, immunotherapy response biomarkers, and sarcoma research.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership for spatial analysis of exceptional cancer survivor samples from 40 countries using Xenium platform. Explicyte performed Xenium 5K spatial transcriptomics on 100+ FFPE samples from the Rosalind study focusing on exceptional survivors of metastatic pancreatic ductal adenocarcinoma.

5Domain Therapeutics
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Partnership agreement in immuno-oncology for novel GPCR-targeting therapies. Collaboration on anti-CCR8 therapeutics with joint webinar on targeting Tregs in solid tumors. Domain Therapeutics focuses on novel GPCR-targeting therapies while Explicyte provides translational insights through tumor microenvironment analysis.

explicyte.com
Strategic tierSupportingTypeTechnology or Integration
Description

Collaboration on sample multiplexing with Xenium platform to improve cost efficiency and throughput for spatial transcriptomics studies. Partnership enables cohort-scale spatial transcriptomics to be performed faster and more cost-effectively.

7ImmunoConcEpT (CNRS/Université de Bordeaux)
Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Research collaboration on immunology studies including vitiligo research. Explicyte performed multiplex immunofluorescence analysis for paired pre/post immune profiling of skin biopsies using automated multiplex IF workflows.

explicyte.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

AI-powered spatial biology company offering image analysis services for tumor microenvironment and biomarker discovery in pharma clinical programs. Comparable in AI-driven spatial biomarker services for immuno-oncology drug development.

TypeOthers
Description

Provider of digital pathology image analysis software (HALO) widely used in pharma translational and clinical research. Comparable as an enabling technology ecosystem participant for digital pathology and spatial biomarker workflows Explicyte operates in.

TypeDirect peer
Description

Specialty precision medicine CRO offering flow cytometry, immunohistochemistry, multiplex immunofluorescence, and biomarker services across immuno-oncology and inflammation. Directly comparable as a histology/immuno-oncology biomarker CRO with similar target customers (biotech, pharma, academic centers).

TypeBroad incumbent
Description

Large oncology-focused clinical laboratory and CRO offering spatial biology, IHC, multiplex immunofluorescence, and clinical trial biomarker services. Comparable in oncology biomarker services but at significantly larger scale and broader geographic footprint.

TypeEmerging player
Description

Genomics and spatial biology services company with immuno-oncology focus, including tumor profiling and biomarker discovery offerings. Comparable in translational oncology services leveraging next-generation sequencing and spatial approaches for pharma/biotech.

TypeBroad incumbent
Description

Larger specialty CRO with biomarker, immuno-oncology, and translational services across pharma and biotech. Comparable in scope of biomarker/translational CRO services but operates at much greater scale across multiple modalities.

TypeEmerging player
Description

Spatial biology platform company offering multiplex immunofluorescence (PhenoCycler/CODEX) and spatial biomarker services, including through service-provider partnerships. Comparable as a spatial biology player, though more of a platform/instrument vendor than a pure CRO.

TypeDirect peer
Description

Tissue-based CRO specializing in quantitative digital pathology and AI-driven image analysis for clinical trials, with strong focus on immuno-oncology biomarker scoring. Directly comparable as an AI/digital pathology CRO serving pharma clinical biomarker needs.

TypeDirect peer
Description

Provides spatial biology services (ChipCytometry, multiplex imaging) and biomarker CRO offerings for immuno-oncology research. Comparable as a specialty spatial biology services provider serving pharma/biotech translational programs.

TypeEmerging player
Description

Spatial biology company offering multiplex immunofluorescence assays and services for tissue biomarker analysis in immuno-oncology and clinical research. Comparable in multiplex IF tissue biomarker services for translational research customers.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Explicyte

Preclinical Contract Research Servicesexplicyte.com

Explicyte is a France-based specialty contract research organization serving biotech, pharmaceutical, AI-bio, and academic cancer-center clients with spatial biology, single-cell, proteomics, and AI-assisted digital pathology services for precision oncology and immuno-oncology drug development.

What Explicyte does

Explicyte is a specialty contract research organization (CRO) focused on precision oncology and immuno-oncology, founded in 2015 by Dr. Alban Bessède and headquartered at the Institut Bergonié Comprehensive Cancer Center in Bordeaux, France. The company delivers research services spanning target discovery, preclinical development, and clinical biomarker analysis for solid tumor drug development, with a particular emphasis on tumor microenvironment and immunotherapy-response biomarkers. Its core technical stack is anchored on a multi-omics spatial biology platform that combines 10x Genomics Xenium single-cell spatial transcriptomics, 10x Visium HD whole-transcriptome spatial profiling, Nanostring GeoMx DSP digital spatial profiling, 10x Chromium X single-cell RNA sequencing, Olink proteomics, flow cytometry, and AI-assisted multiplex IHC/IF digital pathology. Explicyte differentiates through proprietary assays including an ISO-certified multiplex IF assay for tertiary lymphoid structure (TLS) detection and a combined immune contexture panel that integrates CD8 spatial distribution, TLS maturity, and M2 macrophage scoring to predict immunotherapy response in NSCLC. The company is a 10x Genomics Certified Service Provider (the first such provider in France for Xenium studies) and holds ISO 13485:2016 and ISO 9001:2015 certifications for clinical tissue biomarker services.

Explicyte generates revenue through project-based contract research engagements sold to biotechnology companies, pharmaceutical companies, AI/computational biology firms, and comprehensive cancer centers across Europe, North America, and Asia. Pricing is quote-based and negotiated per study with deposit requirements and 30-day payment terms; no standardized tiers are published. The go-to-market model combines direct enterprise sales through PhD-level study directors, presence at major oncology conferences (AACR, ASCO, SITC, ESMO), peer-reviewed publications (40+ in 5 years in Nature, Cell, and cancer-focused journals), co-branded webinars, and free-access therapeutic-program databases used for lead generation. Named enterprise and academic customers include Bayer, GSK, AstraZeneca, Domain Therapeutics, Bioptimus, Cure51, Institut Bergonié, and Gustave Roussy. Beyond service revenue, the company is beginning to monetize proprietary target landscaping through publicly available therapeutic-program databases on anti-STEAP1/2 and anti-Claudin programs.

The operating entity is a brand under Immusmol SAS (Bordeaux-registered private limited company with €50,000 share capital). Explicyte is founder-led with no disclosed external institutional investors or funding rounds. The operating team comprises 25 scientists spanning cell biology, digital pathology, medical oncology, and data science (5 on-site data scientists), supported by a leadership team of CEO (Alban Bessède), CTO (Jean-Philippe Guégan, PhD), CSO (Imane Nafia, PhD), and COO (Loïc Cerf, MSc). The company has processed 10,000+ samples and validated 150+ tumor and immune markers across sponsored studies; two 10x Xenium instruments are now in operation, doubling single-cell spatial transcriptomics capacity compared with 2024.

Explicyte firmographics

Firmographics
Name
Explicyte
Legal name
Immusmol SAS
Website
https://explicyte.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
Explicyte is a France-based specialty contract research organization serving biotech, pharmaceutical, AI-bio, and academic cancer-center clients with spatial biology, single-cell, proteomics, and AI-assisted digital pathology services for precision oncology and immuno-oncology drug development.
Ownership category
akta.pro rank

Explicyte industry classification

Industry
Product category
Preclinical Contract Research Services
NAICS
Medical and Diagnostic Laboratories (62151), Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071), Services-Misc Health & Allied Services, Nec (8090)
akta.pro industry
PRIMARYHLAGANAC
Single-Cell & Spatial Omics Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAGANAI
Bioinformatics, Multi-Omics Data Analysis & Interpretation Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAGADAG
Proteomics & Biomarker Analytical Testing
SECONDARYHLAAAIAF
Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Preclinical CRO services
  • Spatial transcriptomics services
  • Immuno-oncology research
  • Biomarker discovery services
  • Digital pathology services

Where Explicyte is headquartered

Location

Headquarters

HQ city
Bordeaux
HQ country
France
HQ region
Europe

Offices1 record

Markets served

Explicyte business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Contract Research Services: Project-based contract research services for precision oncology and immuno-oncology drug development. Services span discovery (target identification), preclinical (cell-based assays, in vivo models), and clinical (biomarker analysis) stages. Pricing is quote-based, negotiated per study with deposit requirements and 30-day payment terms.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goCustom project-based pricing. No standard tiers or public pricing. Each service proposal is tailored to client requirements with deposits and milestone-based invoicing.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Explicyte product offering

Product offering

Core offering

Explicyte is a specialty contract research organization offering integrated research services in precision oncology and immuno-oncology, from target discovery through preclinical and clinical biomarker analysis. Core capabilities include spatial transcriptomics on the full 10x Genomics suite (Xenium, Visium HD, Chromium X), Nanostring GeoMx DSP digital spatial profiling, automated multiplex IHC/IF digital pathology, single-cell RNA sequencing, cell-based immuno-oncology assays, Olink proteomics, flow cytometry, and bioinformatics, delivered under ISO 13485 and ISO 9001 certifications. Services are sold as project-based studies with custom proposals, deposits, and milestone-based invoicing to biotech, pharma, AI, and academic clients worldwide.

Product overview

Explicyte is a specialty contract research organization (CRO) offering integrated research services in precision oncology and immuno-oncology. The company operates a modular service portfolio spanning target discovery, preclinical development, and clinical biomarker support. Core capabilities include spatial transcriptomics (Xenium, Visium HD, GeoMx), digital pathology (multiplex IHC/IF), cell-based assays, single-cell RNA sequencing (10x Chromium), Olink proteomics, flow cytometry, and bioinformatics. Services are delivered from discovery through clinical trial phases, with ISO 13485/9001 certification for clinical-stage biomarker assays. The company is a 10x Genomics Certified Service Provider across its full spatial and single-cell biology portfolio. Key platforms include spatial transcriptomics for spatial biomarker analysis, cell-based assays for preclinical efficacy and mechanism-of-action studies, digital pathology with AI-driven image analysis, and integrated multi-omics combining transcriptomics, proteomics, and digital pathology.

Differentiator

Problem solved

Functional benefit

Products and services

  • Spatial Transcriptomics Services Spatially resolved transcriptomic profiling using the Nanostring GeoMx Digital Spatial Profiler (WTA, ~18k genes), the 10x Xenium single-cell spatial transcriptomics platform (up to 5K genes), and 10x Visium HD whole-transcriptome spatial biology. Includes custom tissue processing, QC, and bioinformatics analysis on FFPE tumor samples for biotech, pharma, and academic sponsors.
  • Digital Pathology Services Automated multiplex immunofluorescence (mIF) and immunohistochemistry (IHC) staining with high-throughput whole-slide imaging and AI- and/or pathologist-assisted standardized scoring workflows. Validated 150+ tumor and immune markers across sponsored studies for immuno-oncology sponsors.
  • Cell-Based Assays for Immuno-Oncology
  • Biomarker Discovery & Testing Services
  • Single-Cell RNA Sequencing Services
  • Olink Proteomics Services
  • Flow Cytometry Services
  • Target Discovery Services
  • In Vivo Syngeneic Tumor Models
  • TLS Detection & Scoring Service ISO-certified multiplex immunofluorescence (IF) panel for standardized detection and scoring of tertiary lymphoid structures (TLS) in tumor samples. Identifies patients most likely to benefit from cancer immunotherapies. Developed over 5+ years of translational research with publications in Nature Cancer and Nature Medicine.
  • Bioinformatics & Data Science Services Custom data analysis for spatial transcriptomics, bulk RNA-seq, GeoMx DSP datasets, and digitized pathology slides. 10x Genomics data analysis services with 4-week turnaround delivered by 5 on-site data scientists combining computational pipelines with biological interpretation.

Quantifiable outcome

  • 30+ peer-reviewed publications in the past 5 years demonstrating scientific expertise in immuno-oncology
  • +2 more outcomes

Companies that use Explicyte

Customer profile

Named customers8 records

Segments4 records

Ideal customer profiles3 records

Explicyte technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature5 records

Explicyte partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core, major and supporting.

  • 10x GenomicscoreTechnology or Integration · 1 January 2024Certified Service Provider partnership for the full 10x Genomics single-cell and spatial biology portfolio including Chromium X, Visium HD, and Xenium platforms. Enables Explicyte to provide validated spatial transcriptomics services on FFPE tumor samples using industry-leading technology platforms.
  • Institut BergoniécoreStrategic or Co-development PartnerComprehensive partnership for translational research programs in immuno-oncology. Located at the Institut Bergonié Comprehensive Cancer Center, Explicyte collaborates on clinical trials, biomarker discovery studies, and shares access to clinical samples and expertise. Multiple joint publications in Nature Cancer, Nature Medicine, and other journals.
  • Gustave RoussycoreStrategic or Co-development PartnerCollaboration on multiple clinical trials and translational research programs including PEMBROSARC, REGOMUNE, and precision medicine studies. Joint publications on tertiary lymphoid structures, immunotherapy response biomarkers, and sarcoma research.
  • Cure51coreStrategic or Co-development PartnerPartnership for spatial analysis of exceptional cancer survivor samples from 40 countries using Xenium platform. Explicyte performed Xenium 5K spatial transcriptomics on 100+ FFPE samples from the Rosalind study focusing on exceptional survivors of metastatic pancreatic ductal adenocarcinoma.
  • Domain TherapeuticsmajorStrategic or Co-development PartnerPartnership agreement in immuno-oncology for novel GPCR-targeting therapies. Collaboration on anti-CCR8 therapeutics with joint webinar on targeting Tregs in solid tumors. Domain Therapeutics focuses on novel GPCR-targeting therapies while Explicyte provides translational insights through tumor microenvironment analysis.
  • BioptimussupportingTechnology or IntegrationCollaboration on sample multiplexing with Xenium platform to improve cost efficiency and throughput for spatial transcriptomics studies. Partnership enables cohort-scale spatial transcriptomics to be performed faster and more cost-effectively.
  • ImmunoConcEpT (CNRS/Université de Bordeaux)supportingStrategic or Co-development PartnerResearch collaboration on immunology studies including vitiligo research. Explicyte performed multiplex immunofluorescence analysis for paired pre/post immune profiling of skin biopsies using automated multiplex IF workflows.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Explicyte competitors and assessment

Company assessment

Emerging players

  • Nucleai: AI-powered spatial biology company offering image analysis services for tumor microenvironment and biomarker discovery in pharma clinical programs. Comparable in AI-driven spatial biomarker services for immuno-oncology drug development.
  • Personalis: Genomics and spatial biology services company with immuno-oncology focus, including tumor profiling and biomarker discovery offerings. Comparable in translational oncology services leveraging next-generation sequencing and spatial approaches for pharma/biotech.
  • Akoya Biosciences: Spatial biology platform company offering multiplex immunofluorescence (PhenoCycler/CODEX) and spatial biomarker services, including through service-provider partnerships. Comparable as a spatial biology player, though more of a platform/instrument vendor than a pure CRO.
  • Ultivue: Spatial biology company offering multiplex immunofluorescence assays and services for tissue biomarker analysis in immuno-oncology and clinical research. Comparable in multiplex IF tissue biomarker services for translational research customers.

Others

  • Indica Labs: Provider of digital pathology image analysis software (HALO) widely used in pharma translational and clinical research. Comparable as an enabling technology ecosystem participant for digital pathology and spatial biomarker workflows Explicyte operates in.

Direct peers

  • CellCarta: Specialty precision medicine CRO offering flow cytometry, immunohistochemistry, multiplex immunofluorescence, and biomarker services across immuno-oncology and inflammation. Directly comparable as a histology/immuno-oncology biomarker CRO with similar target customers (biotech, pharma, academic centers).
  • Flagship Biosciences: Tissue-based CRO specializing in quantitative digital pathology and AI-driven image analysis for clinical trials, with strong focus on immuno-oncology biomarker scoring. Directly comparable as an AI/digital pathology CRO serving pharma clinical biomarker needs.
  • Canopy Biosciences (a Bruker company): Provides spatial biology services (ChipCytometry, multiplex imaging) and biomarker CRO offerings for immuno-oncology research. Comparable as a specialty spatial biology services provider serving pharma/biotech translational programs.

Broad incumbents

  • NeoGenomics Laboratories: Large oncology-focused clinical laboratory and CRO offering spatial biology, IHC, multiplex immunofluorescence, and clinical trial biomarker services. Comparable in oncology biomarker services but at significantly larger scale and broader geographic footprint.
  • Precision for Medicine: Larger specialty CRO with biomarker, immuno-oncology, and translational services across pharma and biotech. Comparable in scope of biomarker/translational CRO services but operates at much greater scale across multiple modalities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Explicyte social profiles

Digital presence

Explicyte compliance and trust

Trust signal

Compliance2 records

Explicyte financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Explicyte leadership team

Management profile

Number of profiles

Profiles6 records

Explicyte funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Explicyte M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Explicyte

What does Explicyte do?

Explicyte is a specialty contract research organization offering integrated research services in precision oncology and immuno-oncology, from target discovery through preclinical and clinical biomarker analysis. Core capabilities include spatial transcriptomics on the full 10x Genomics suite (Xenium, Visium HD, Chromium X), Nanostring GeoMx DSP digital spatial profiling, automated multiplex IHC/IF digital pathology, single-cell RNA sequencing, cell-based immuno-oncology assays, Olink proteomics, flow cytometry, and bioinformatics, delivered under ISO 13485 and ISO 9001 certifications. Services are sold as project-based studies with custom proposals, deposits, and milestone-based invoicing to biotech, pharma, AI, and academic clients worldwide.

Is Explicyte a public or private company?

Explicyte is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Explicyte founded?

Explicyte was founded in 2015. It employs 11 to 50 people.

Where is Explicyte based?

Explicyte is headquartered in Bordeaux, France, in the Europe region.

How does Explicyte make money?

One revenue line is on record: contract Research Services.

Who are Explicyte's main competitors?

Emerging players on record are Nucleai, Personalis, Akoya Biosciences and Ultivue. Indica Labs is listed as an others. Direct peers are CellCarta, Flagship Biosciences and Canopy Biosciences (a Bruker company). Broad incumbents are NeoGenomics Laboratories and Precision for Medicine.

Does Explicyte have an API?

No public API is recorded for Explicyte.

What industry is Explicyte in?

Explicyte's product category is Preclinical Contract Research Services. Its primary akta.pro industry code is HLAGANAC, Single-Cell & Spatial Omics Services, with a secondary code of HLAGANAI, Bioinformatics, Multi-Omics Data Analysis & Interpretation Services. Its NAICS code is 62151 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales